Hormonal dysfunction in patients with chronic obstructive pulmonary disease  by Sobhy, Therese et al.
Egyptian Journal of Chest Diseases and Tuberculosis (2012) 61, 75–79The Egyptian Society of Chest Diseases and Tuberculosis
Egyptian Journal of Chest Diseases and Tuberculosis
www.elsevier.com/locate/ejcdt
www.sciencedirect.comORIGINAL ARTICLEHormonal dysfunction in patients with chronic
obstructive pulmonary diseaseTherese Sobhy a, Tyseer Mohamed Eiada b, Amany Abou Zeid c,*,
Maysa Mohamed Sharaf Eldin ca Department of Chest at Mataria Teaching Hospital, Egypt
b Department of Clinical Pathology at Kasr El Aini Hospital, Cairo University, Egypt
c Department of Chest at Kasr El Aini Hospital, Cairo University, EgyptReceived 3 April 2012; accepted 13 April 2012
Available online 4 February 2013*
E-
Pe
D
04
OpKEYWORDS
COPD;
Thyroid dysfunction;
Insulin like growth hormoneCorresponding author. Tel.:
mail address: chestmrcp@ya
er review under responsibil
iseases and Tuberculosis.
Production an
22-7638 ª 2013 The Egyptia
en access under CC BY-NC-ND li+20 100
hoo.com
ity of Th
d hostin
n Society
httcense.Abstract Background: Systemic response to chronic disease in COPD patients might cause hor-
monal imbalance which in turn affects the severity of the disease. The severity of hypoxia in COPD
patients causes alterations in thyroid function tests and IGF-1 levels.
Methods: This work was carried on 50 COPD patients diagnosed and classiﬁed according to
GOLD criteria and 20 healthy controlled subjects. All subjected to full clinical history, examination,
chest X-ray and spirometry. Levels of TT3, TT4, FT3, FT4, IGF-1 and insulin were measured.
Results: TT4, FT3, FT4, TSH, and insulin levels were normal in all COPD. Despite the TT3 hor-
mone level were normal in all stages of COPD, there is reduction in hormone levels in stage III and
stage IV than control subjects. There is also reduction in TT3/TT4 ratio in severe COPD and there
is correlation between TT3/TT4 ratio and PaO2 in stage III and stage IV but no correlation between
TT3/TT4 ratio and PaO2 in stage I and stage II. IGF-1 hormone levels were variable among dif-
ferent stages of COPD.
Conclusion: There is was no signiﬁcant difference between some hormonal levels in COPD and
in controls, accordingly hormonal replacement therapy in these patients is doubtful.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1744274.
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Endocrine changes in chronic obstructive pulmonary disease
patients are poorly documented. The pathogenesis and clinical
manifestation of chronic obstructive pulmonary disease are
not restricted to pulmonary inﬂammation and structural
remodeling. Rather, this disorder is associated with clinically
signiﬁcant systematic and alteration in biochemistry and organ
function. This may include alteration in the relative levels oris. Production and hosting by Elsevier B.V.
.10.014
76 T. Sobhy et al.activities of endocrine hormone such as insulin and growth
hormone [1].
The thyroid hormone enhances mitochondrial oxidation
and, thus, augments metabolic rate. This effect on metabolic
rate is probably responsible for the association between the
thyroid hormone and respiratory drive. Limited data on the
prevalence of thyroid diseases among patients with COPD
are available. Yet, several characteristics of patients with
COPD could potentially increase their likelihood of developing
hypothyroidism and hyperthyroidism [2].
Little is known about circulating growth hormone or IGF-1
concentration. Some author ﬁnd a decrease in growth hor-
mone or IGF-1, others an increase. An increase of growth hor-
mone might reﬂect a nonspeciﬁc response of the body to stress
(for instance, hypoxemia). Until now, only on controlled study
on growth hormone supplementation has been published,
which however did not reveal any functional beneﬁts. Before
growth hormone supplementation can be advised as part of
the treatment in chronic obstructive pulmonary disease, fur-
ther controlled studies must be performed to investigate its
functional efﬁcacy [3].
In this study we measured different hormonal assay includ-
ing thyroid hormones, IGF-1 and insulin in an attempt to de-
tect some hormonal abnormalities in patients with COPD, we
also correlated different hormonal level with severity of
COPD.
Methods
This is a prospective study including 50 patients with COPD
diagnosed and classiﬁed according to GOLD 2009 criteria [4]
and twenty healthy non smoker volunteers as control.
Between 2008 and 2010 the patients were recruited from the
outpatient clinic of El Mataria teaching Hospitals according to
the inclusion criteria which include, symptoms of chronic
bronchitis, evidence of airway obstruction according to GOLD
study 2009 and no improvement in FEV1 of more than 10%
after inhalation of 200 mg of Salbutamol. However, we ex-
cluded patients on oral glucocorticoids or with any other drugTable 1 Patients characteristic.
Characterestics COPD patients
Age 38–71
56.5 ± 8.1
Sex All males
BMI 19.2–33.9
24.6 ± 3.7
Stage of disease Stage I No. 12
Stage II No. 19
Stage III No. 1
Stage IV No. 9
Spirometry
FEV1% 57.6 ± 19.3
FEV1/FVC 57.2 ± 10.9
Arterial blood gases
pH 7.4 ± 0.02
paO2 74 ± 9.33
paCO2 44.6 ± 6.54
Fasting blood sugar 2 h postprandial 87.72 ± 13.4
115.3 ± 26.1known to affect thyroid function such as amiodarone or io-
dine-containing contrast media. Clinical evidence of thyroid
disease or coexistence of other diseases altering thyroid func-
tion tests. Patients with fasting hyperglycemia, positive urine
glucose or renal failure.
Patients were subjected to clinical examination, chest X-
ray, spirometry (Spirovit SP-10-Schiller, Switzerland), com-
plete blood picture, fasting and two hours post prandial blood
glucose. Hormonal assay using enzyme linked immunosorbent
assay technique measuring the following hormonal levels.
(A) Total thyroxin (TT4).
(B) Total triiodthyronine (TT3).
(C) Thyroid stimulating hormone (TSH).
(D) Free thyroxine (FT4).
(E) Free triiodthyronine (FT3).
(F) Fasting serum insulin hormone level.
(G) Insulin growth factor range (IGF-1).
Results
Between 2008 and 2010, we measured the hormonal levels of
thyroid gland, TSH and insulin and IGF-1 in 50 patients with
COPD and 20 controls.
The patient characteristics are summarized in Table 1.
There was a statistical signiﬁcant reduction in FEV1, FEV1/
FVC, paO2 and paCO2 between patients with COPD
(No. = 50) and controls (No. = 20).
There was no statistical signiﬁcant difference between pa-
tients with COPD and controls in total T3 and T4, TSH, Free
T3 and T4 or insulin levels in this study (Table 2).
Hormonal levels according to stages of COPD showed a
statistical difference between COPD patients and controls in
total iodothyrionine (T3) levels. However, no signiﬁcant
differences were detected in other hormonal parameters
(Table 3).
Calculated TT3/TT4 did not correlate with paO2 in stage I
and stage II, however there was a strong positive correlationNo. 50 Control No. 20 P-value
40–67 0.09
52.9 ± 8.3
All males
22.9–28.7 0.89
24.5 ± 1.47
(24%)
(38%)
0 (20%)
(18%)
107.7 ± 8.9 0.001
99.7 ± 9.45 0.001
7.41 ± 0.02 0.012
82.8 ± 4.5 0.001
38.6 ± 1.2 0.001
83.6 ± 11.1 0.26
99.9 ± 22.8 0.02
Table 2 Different hormonal levels between COPD patients
and controls.
Hormones COPD patients Controls P - value
Total T3 (ng%)
Range 80  180 120  200 0.027
Mean + SD 140.4 ± 25.7 155 ± 20.9
Total T4 (lg%)
Range 5.7  12 6.5  12 0.16
Mean + SD 8.5 ± 1.55 9.1 ± 1.6
TSH (lIU/dl)
Range 0.3  3.6 0.09  4.5 0.29
Mean + SD 1.8 ± 0.88 1.15 ± 1.16
Free T3 (pg/ml)
Range 1.2  3.7 1.7  4.2 0.3
Mean + SD 2.6 ± 0.4 2.8 ± 0.6
Free T4 (ng/dl)
Range 0.68  1.9 0.08  1.7 0.27
Mean + SD 1.2 ± 0.23 1.12 ± 0.38
Insulin (lIU/ml)
Range 6.4  24.8 10  20 0.5
Mean + SD 15.7 ± 3.7 15 ± 2.4
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(Fig. 1).
The IGF1 level in chronic obstructive lung disease was: In
mild stage (stage I) (25%) of patients the hormone levels were
reduced, while in (75%) of patients the hormone levels were
within normal limits. In moderate stage (stage II) (63.16%)
of patients the hormone levels were reduced, while in
(36.84%) of patients the hormone levels were within normal
limits. In severe stage (stage III) (60%) of patients the hor-
mone levels were reduced, while in (40%) of patients the hor-
mone levels were within normal limits. In very severe stage
(stage IV) (22.22%) of patients the hormone levels were re-Table 3 Different hormonal level in relation to disease stage and it
Hormonal level Stage I Stage
TT3
Mean + SD 162.9 ± 20.6 142.6 ±
p-value 0.3 0.05
TT4
Mean + SD 8.9 ± 1.7 8.5 ±
p-value 0.6 0.1
TSH
Mean + SD 2.2 ± 0.9 1.8 ±
p-value 0.1 0.4
FT3
Mean + SD 2.7 ± 0.4 2.7 ±
p-value 0.7 0.6
FT4
Mean + SD 1.2 ± 0.2 1.2 ±
p-value 0.6 0.2
Insulin
Mean + SD 14.4 ± 5.4 16.3 ±
p-value 0.1 0.1duced, while in (77.78%) of patients the hormone levels were
within normal limits (Graph 1–4).
Discussion
Systemic response to chronic disease in COPD patients might
cause hormonal imbalance which in turn affects the severity of
the disease. The severity of hypoxia in COPD patients causes
alterations in thyroid function tests and IGF-1 levels [5].
This work was carried out to investigate thyroid function,
insulin hormone level, and insulin like growth factor-1 (IGF-
1) levels in patients with chronic obstructive pulmonary disease
COPD, presenting a spectrum in disease severity, as indicated
by the various degrees of airway obstruction.
In the present study the hormonal level of total triiodothy-
ronine (TT3) were normal in all COPD patients, however in
stage III and IV there was a reduction in the hormone level
in these stages than control subject and in comparison to stage
I and II. These results agree with other studies that found no
signiﬁcant differences between levels of TT3 in COPD and
controls [6,7]. Other investigators found that TT3 is reduced
in all COPD patients especially those with hypoxemia than
control subjects [8]. Regarding total thyroxine (TT4) the hor-
mone level was normal in COPD patients with no statistical
difference in comparison with control, this agrees with other
studies [6,7].
The calculated TT3 to TT4 ratio was used, as this ratio has
been proven to be a useful tool in studying the peripheral con-
version of thyroxin to triiodothyronine in various disease
states [9]. In the present study there is reduction in TT3/TT4
ratio in stage III and stage IV COPD patients and there was
a strong positive correlation between TT3/TT4 ratio and
PaO2 in stage III and stage IV (r= 0.475, and P= 0.040), this
agree with the results in other studies [6,8].
This pattern of hormonal changes suggests that hypoxemia
acts not only at the central levels of hypothalamic-pituitary-s signiﬁcance with controls.
II Stage III Stage IV
17.9 127 ± 21.5 120.6 ± 28.1
0.002 0.001
1.4 8.5 ± 1.6 8.4 ± 1.8
0.29 0.3
0.8 1.8 ± 1 1.4 ± 0.9
0.5 0.6
0.3 2.6 ± 0.4 2.6 ± 0.6
0.3 0.3
0.1 1.2 ± 0.3 1.2 ± 0.3
0.7 0.7
1.7 16.2 ± 5.4 16 ± 1.5
0.5 0.3
Figure 1 Correlation between calculated TT3/TT4 ratio and paO2.
Graph 1 Percentage of patients with abnormal IGF-1 in stage I.
Graph 2 Percentage of patients with abnormal IGF-1 in stage II.
Graph 3 Percentage of patients with abnormal IGF-1 in stage
III.
Graph 4 Percentage of patients with abnormal IGF-1 in stage
IV.
78 T. Sobhy et al.thyroid, but also interferes with the peripheral metabolism and
turnover of thyroid hormone.
In this study the free T3 and T4 levels were normal in all
stages of COPD in comparison to the controls, this was the re-
sults in other researches [7,10]. Other authorities found that
free T3 and T4 were higher in COPD than the control and
the authors could not explain their observation [11,12]. How-
ever, other studies could demonstrate lower level of FT3 dur-
ing exacerbations and partially regress after one month when
the disease is stabilized [8].
In this study the level of TSH and insulin were normal in all
COPD patients, and this agrees with other studies [6,12,13].It was concluded that thyroid dysfunction ascribed to
chronic COPD is probably related to confounding factors
and not to hypoxemia or hypercapnia. So far, there is no evi-
dence that thyroid function is consistently altered in COPD,
except perhaps in a subgroup of patients with severe
hypoxemia.
Circulating insulin like growth factor-1 (IGF-1) level was
used as a marker of growth hormone (GH) action because
IGF-1 has a longer half life than GH, and its concentration
integrates the pulsatile release of GH [1]. In our study we ob-
served the reduction in IGF-1 level in different stages of
COPD. Little information is available regarding circulating
Hormonal dysfunction in patients with chronic obstructive pulmonary disease 79growth hormone or insulin like growth factors-1 (IGF-1) levels
in chronic obstructive pulmonary disease (COPD). The data
that exist suggest that insulin like growth factors-1 (IGF-1) lev-
els in stable chronic obstructive pulmonary disease (COPD)
patients tend to be low consistent with the impression that
the growth hormone axis is suppressed by chronic disease. [14].
The mechanisms by which COPD alters endocrine function
are incompletely understood but likely involve hypoxemia,
hypercapnia, and systemic inﬂammation. Altered endocrine
function can worsen the clinical manifestations of COPD
through several mechanisms.
In this study we demonstrated some hormonal changes in
patients of COPD which could be attributed to systemic man-
ifestation of COPD e.g. cachexia, muscle wasting, however
more sophisticated investigation should be done especially to
evaluate the role of hormonal replacement therapy.
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